Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy
Journal for ImmunoTherapy of Cancer · 2025-11 · 13 (11) · e012138
DOI: 10.1136/jitc-2025-012138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 12.11.2025. Verfasst von Salvatore Russo und 20 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Finland. Hauptthemen laut MEDLINE: Tumor Microenvironment, DNA (Cytosine-5-)-Methyltransferase 1, Immunotherapy, Extracellular Vesicles. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Business Finland, Jane and Aatos Erkko Foundation, Cancer Foundation Finland.
Abstract (Originalsprache)
Background
The efficacy of immunotherapy is often hindered by the suppression of immune responses via the tumor microenvironment (TME). The presence of cancer cells forces other proximal non-cancerous cells to support tumor growth and persistence. A clear example of this cancerous-to-non-cancerous communication is represented by the accumulation of myeloid-derived suppressor cells (MDSCs) within the TME. Several studies have convergently shown that the overexpression of DNA-methyl-transferase-1 (DNMT1) in these cells results in protection from necroptosis and enhanced accumulation in vivo. Conversely, targeting DNMT1 through hypo-methylating agents has shown promising therapeutic potential by not only reducing the levels of MDSCs but also enhancing cancer immunogenicity and the efficacy of immune checkpoint inhibitors (ICI).
Methods
Murine 4T1 (triple-negative breast cancer (TNBC)) and CT26 (colon carcinoma) cell lines were cultured under standard conditions and used to generate tumor models in BALB/c mice. An oncolytic adenovirus expressing a DNMT1-targeting short hairpin RNA (OAd.shDNMT1) was engineered and validated for DNMT1 knockdown and genome-wide methylation reduction. Small extracellular vesicles (sEVs) were isolated from virus-infected cancer cells and characterized for RNA content and uptake by MDSCs. MDSC differentiation and suppressive function were assessed in vitro using flow cytometry and co-culture assays with murine splenocytes. In vivo, tumor-bearing mice received intratumoral OAd.shDNMT1, systemic decitabine, or immune checkpoint inhibitors (anti-Programmed cell Death protein-1), and tumor growth, immune infiltration, and systemic MDSC levels were evaluated.
Results
In this study, we report that, by using virally infected TNBC murine cells as a source for shDNMT1-loaded sEVs, OAd.shDNMT1 successfully reduced MDSC levels in vitro and in vivo. Furthermore, the co-administration with ICI resulted in a significant tumor growth reduction in mice bearing poorly immunogenic TNBC 4T1 cells. Also, our treatment promoted antitumor immunity, prolonged survival, and complete tumor eradication in modestly immunogenic colon CT26 cancer cells.
Conclusion
This multifaceted strategy, based on OV-mediated immune stimulation and reduction of MDSC levels via sEVs, may improve clinical outcomes and the success of immuno-based regimens for patients facing MDSC-rich and highly aggressive cancer subtypes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Immunovirotherapy, Drug Research Program, University of Helsinki Faculty of Pharmacy, Helsinki, Finland.
- Digital Precision Cancer Medicine Flagship (iCAN), University of Helsinki, Helsinki, Finland.
- TRIMM, Translational Immunology Research Program, University of Helsinki, Helsinki, Finland.
- Drug Research Program, Division of Pharmaceutical Biosciences, Faculty of Pharmacy, University of Helsinki, Helsinki, Finland.
- Helsinki Institute of Life Science (HiLIFE), University of Helsinki, Helsinki, Finland.
- GeneCellNano flagship, University of Helsinki, Helsinki, Finland.
Förderung
- Business Finland
- Jane and Aatos Erkko Foundation
- Cancer Foundation Finland
- Suomen Farmaseuttinen Yhdistys
- ERC EIC Brainstorm
- Research Council of Finland
- Medicinska Understödsföreningen Liv och Hälsa
- Sigrid Juséliuksen Säätiö
Zitieren
APA
Russo, S., Giannoula, Y., Feola, S., Cerioni, J., Hamdan, F., Chiaro, J., Ha Dang, A. T., Bottega, P., Feodoroff, M., Fusciello, M., Stigzelius, V., D'Amico, C., Caiazza, C., Antignani, G., D'Alessio, F., Sakalauskaite, M., Petryk, J., Bell, J., Ilkow, C., …, & Cerullo, V. (2025). Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy. Journal for ImmunoTherapy of Cancer, 13(11), e012138. https://doi.org/10.1136/jitc-2025-012138
Vancouver
Russo S, Giannoula Y, Feola S, Cerioni J, Hamdan F, Chiaro J, et al. Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy. Journal for ImmunoTherapy of Cancer. 2025;13(11):e012138. doi:10.1136/jitc-2025-012138
BibTeX
@article{Russo2025,
author = {Russo, Salvatore and Giannoula, Yvonne and Feola, Sara and Cerioni, Justin and Hamdan, Firas and Chiaro, Jacopo and Ha Dang, Anja Thu and Bottega, Paolo and Feodoroff, Michaela and Fusciello, Manlio and Stigzelius, Virpi and D'Amico, Carmine and Caiazza, Carmen and Antignani, Gabriella and D'Alessio, Federica and Sakalauskaite, Milda and Petryk, Julia and Bell, John and Ilkow, Carolina and Grönholm, Mikaela and Cerullo, Vincenzo},
title = {Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy},
journal = {Journal for ImmunoTherapy of Cancer},
year = {2025},
volume = {13},
number = {11},
pages = {e012138},
doi = {10.1136/jitc-2025-012138}
}
EUVIMED